ATYR

aTyr Pharma, Inc. NASDAQ Listed May 7, 2015

Healthcare ·Biotechnology ·US · atyrpharma.com

$0.92

Pre-mkt $0.57 +8.20%

Mkt Cap $90.4M

52w Low $0.64 4.2% of range 52w High $7.29

50d MA $0.85 200d MA $1.69

P/E (TTM) -1.0x

EV/EBITDA -1.0x

P/B 1.1x

Debt/Equity 0.2x

ROE -109.8%

P/FCF -1.2x

RSI (14) —

ATR (14) —

Beta 0.65

50d MA $0.85

200d MA $1.69

Avg Volume 1.6M

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.

SIC Code

2836

CIK (SEC)

1339970

Phone

858 731 8389

10240 Sorrento Valley Road · San Diego, CA 92121 · US

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 5, 2026	AMC	-0.18	-0.14	+22.2%	0.90	-3.1%	-8.7%	+9.2%	+4.0%	-1.5%	-5.9%	—
Nov 6, 2025	AMC	-0.20	-0.26	-30.0%	0.77	-2.6%	+6.0%	-3.3%	-0.3%	-8.2%	-1.3%	—
Aug 7, 2025	AMC	-0.18	-0.22	-22.2%	5.24	+0.0%	+1.1%	+5.8%	-6.8%	-1.5%	-3.1%	—
May 7, 2025	AMC	-0.19	-0.17	+10.5%	3.16	-1.6%	+5.7%	-1.8%	-1.2%	+2.2%	-8.5%	—
Mar 13, 2025	AMC	-0.23	-0.18	+21.7%	3.99	-8.3%	-0.5%	+1.0%	-3.5%	-0.8%	-2.1%	—
Nov 7, 2024	AMC	-0.22	-0.23	-4.5%	3.10	-1.6%	+0.6%	+7.7%	+3.9%	+0.9%	-9.4%	—
Aug 13, 2024	AMC	-0.22	-0.23	-4.5%	1.74	+5.7%	+6.3%	+8.1%	-4.5%	-1.0%	-1.6%	—
May 2, 2024	AMC	-0.24	-0.23	+4.2%	—	—	—	—	—	—	—	—
Mar 14, 2024	AMC	-0.24	-0.25	-4.2%	—	—	—	—	—	—	—	—
Sep 30, 2023	AMC	-0.23	-0.20	+13.3%	—	—	—	—	—	—	—	—
Jun 30, 2023	AMC	-0.28	-0.22	+19.7%	—	—	—	—	—	—	—	—
Mar 31, 2023	AMC	-0.35	-0.29	+18.5%	—	—	—	—	—	—	—	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Nov 7	RBC Capital	Maintains	Sector Perform → Sector Perform	—	$0.77	$0.75	-2.6%	+6.0%	-3.3%	-0.3%	-8.2%	-1.3%
Sep 16	Wells Fargo	Downgrade	Overweight → Equal Weight	—	$1.01	$1.08	+6.9%	+6.9%	-5.6%	+2.9%	-5.5%	+5.8%
Sep 16	RBC Capital	Downgrade	Outperform → Sector Perform	—	$1.01	$1.08	+6.9%	+6.9%	-5.6%	+2.9%	-5.5%	+5.8%
Sep 15	LUCID CAPITAL MARKETS	Downgrade	Buy → Neutral	—	$6.03	$1.26	-79.1%	-83.3%	+6.9%	-5.6%	+2.9%	-5.5%
Sep 15	Leerink Partners	Downgrade	Outperform → Market Perform	—	$6.03	$1.26	-79.1%	-83.3%	+6.9%	-5.6%	+2.9%	-5.5%
Sep 15	Jones Trading	Downgrade	Buy → Hold	—	$6.03	$1.26	-79.1%	-83.3%	+6.9%	-5.6%	+2.9%	-5.5%
Sep 15	HC Wainwright & Co.	Downgrade	Buy → Neutral	—	$6.03	$1.26	-79.1%	-83.3%	+6.9%	-5.6%	+2.9%	-5.5%
Sep 15	Cantor Fitzgerald	Downgrade	Overweight → Neutral	—	$6.03	$1.26	-79.1%	-83.3%	+6.9%	-5.6%	+2.9%	-5.5%
Aug 22	Jefferies	Maintains	Buy → Buy	—	$4.95	$5.11	+3.2%	+8.1%	-3.6%	-0.4%	+0.6%	+3.5%
Jun 20	Wells Fargo	Maintains	Overweight → Overweight	—	$5.17	$5.49	+6.2%	+1.0%	-4.6%	+6.6%	-3.8%	+3.9%
Jun 4	HC Wainwright & Co.	Maintains	Buy → Buy	—	$5.39	$5.50	+2.0%	-4.6%	+4.1%	+0.6%	+1.3%	+0.9%
May 19	HC Wainwright & Co.	Maintains	Buy → Buy	—	$3.27	$3.30	+0.9%	+5.2%	+1.5%	+7.4%	+1.3%	-1.3%
Mar 14	HC Wainwright & Co.	Maintains	Buy → Buy	—	$3.99	$3.66	-8.3%	-0.5%	+1.0%	-3.5%	-0.8%	-2.1%
Dec 10	HC Wainwright & Co.	Maintains	Buy → Buy	—	$3.53	$3.60	+2.0%	-6.8%	-3.6%	-4.7%	+1.3%	-1.0%
Dec 3	HC Wainwright & Co.	Maintains	Buy → Buy	—	$3.56	$3.56	+0.0%	-6.5%	+0.0%	-1.8%	+2.8%	+5.1%
Oct 29	HC Wainwright & Co.	Maintains	Buy → Buy	—	$3.32	$3.47	+4.5%	+0.0%	-5.7%	-0.3%	-2.6%	+1.3%
Aug 15	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.85	$1.88	+1.6%	+8.1%	-4.5%	-1.0%	-1.6%	+1.1%
Aug 14	RBC Capital	Maintains	Outperform → Outperform	—	$1.74	$1.84	+5.7%	+6.3%	+8.1%	-4.5%	-1.0%	-1.6%
Aug 1	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.98	$2.02	+2.0%	-1.5%	-6.2%	+2.7%	-0.5%	-4.8%
Jul 22	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.64	$1.70	+3.7%	+13.4%	+0.5%	+3.2%	+15.5%	-0.4%
May 14	HC Wainwright & Co.	Maintains	Buy → Buy	—	—	—	—	—	—	—	—	—
May 3	HC Wainwright& Co.	Maintains	Buy → Buy	—	—	—	—	—	—	—	—	—
May 3	HC Wainwright & Co.	Maintains	Buy → Buy	—	—	—	—	—	—	—	—	—
Mar 15	RBC Capital	Maintains	Outperform → Outperform	—	—	—	—	—	—	—	—	—
Mar 15	HC Wainwright & Co.	Maintains	Buy → Buy	—	—	—	—	—	—	—	—	—
Feb 21	HC Wainwright & Co.	Maintains	Buy → Buy	—	—	—	—	—	—	—	—	—

Data updated apr 24, 2026 7:44pm · Source: massive.com